Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-07-0138
European Journal of Endocrinology, Vol 157, Issue 3, 279-284
Copyright © 2007 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florio, P
Right arrow Articles by Petraglia, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florio, P
Right arrow Articles by Petraglia, F

CLINICAL STUDY

Maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) levels in post-term pregnancy: effect of prostaglandin administration

P Florio, P J Lowry1, C Benedetto2, L Galleri, M Torricelli, A Giovannelli, R Battista, F M Reis and F Petraglia

Department of Pediatrics, Section of Obstetrics and Gynecology, Obstetrics and Reproductive Medicine, University of Siena, Policlinico ‘Le Scotte’ Viale Bracci, 53100 Siena, Italy 1 Department of Biochemistry and Physiology, University of Reading, Whiteknights, Reading, UK and 2 Department of Obstetrics and Gynecology, University of Torino, Torino, Italy

(Correspondence should be addressed to P Florio; Email: florio{at}unisi.it)

Objective: Placental corticotropin-releasing factor (CRF) affects myometrial contractility and the secretion of several uterotonins such as prostaglandins (PGs); however, the activity of CRF is counteracted by CRF-binding protein (CRF-BP). At term and pre-term labor, CRF levels in maternal plasma are highest whereas those of CRF-BP are falling, and the cause of this fall is unknown. Thus, in this study, we investigated the effect of PG administration for labor induction on maternal plasma CRF and CRF-BP concentrations.

Design: Maternal plasma CRF and CRF-BP levels were assayed before and after (2 h later) induction of labor by intracervical administration of prostaglandin E2 (PGE2), and at delivery in a group of healthy post-term pregnancies (n=18). Controls were women at term out of labor (n=22), who subsequently progressed to deliver a healthy singleton baby.

Methods: CRF was measured by two-site immunoradiometric assay, and CRF-BP was assayed by radioimmunoassay.

Results: Maternal plasma CRF levels were significantly (P<0.0001) lower and CRF-BP significantly (P<0.0005) higher in post-term than in term pregnancies. With respect to induction of labor, 2 mg PGE2 were sufficient to increase maternal plasma CRF levels at delivery (P<0.005). While 0.5 mg PGE2 significantly decreased maternal plasma CRF-BP levels at delivery (P<0.001), 2.0 mg PGE2 significantly reduced CRF-BP concentrations both after 2 h (P<0.05) and at delivery (P<0.0001).

Conclusions: In the light of the well-known stimulation of prostaglandin release by CRF, these data suggest a positive feedback effect of PGE2 on maternal CRF release during induced labor.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 European Society of Endocrinology.